AllianceBernstein’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-72,228
| Closed | -$809K | – | 3148 |
|
|
2017
Q3 | $809K | Sell |
72,228
-162,500
| -69% | -$1.79M | ﹤0.01% | 2381 |
|
|
2017
Q2 | $2.58M | Buy |
234,728
+46,680
| +25% | +$467K | ﹤0.01% | 1652 |
|
|
2017
Q1 | $1.84M | Sell |
188,048
-131,950
| -41% | -$1.32M | ﹤0.01% | 1876 |
|
|
2016
Q4 | $3.46M | Buy |
319,998
+1,890
| +0.6% | +$18.9K | ﹤0.01% | 1430 |
|
|
2016
Q3 | $3.26M | Buy |
318,108
+158,070
| +99% | +$1.72M | ﹤0.01% | 1405 |
|
|
2016
Q2 | $2.09M | Buy |
160,038
+21,540
| +16% | +$282K | ﹤0.01% | 1670 |
|
|
2016
Q1 | $1.52M | Buy |
138,498
+53,190
| +62% | +$473K | ﹤0.01% | 1823 |
|
|
2015
Q4 | $785K | Sell |
85,308
-1,220
| -1% | -$10.2K | ﹤0.01% | 2251 |
|
|
2015
Q3 | $601K | Sell |
86,528
-200
| -0.2% | -$1.71K | ﹤0.01% | 2418 |
|
|
2015
Q2 | $852K | Hold |
86,728
| – | – | ﹤0.01% | 2364 |
|
|
2015
Q1 | $768K | Hold |
86,728
| – | – | ﹤0.01% | 2319 |
|
|
2014
Q4 | $760K | Sell |
86,728
-12,000
| -12% | -$97.1K | ﹤0.01% | 2344 |
|
|
2014
Q3 | $680K | Sell |
98,728
-3,100
| -3% | -$18.6K | ﹤0.01% | 2402 |
|
|
2014
Q2 | $536K | Sell |
101,828
-949
| -0.9% | -$4.62K | ﹤0.01% | 2499 |
|
|
2014
Q1 | $468K | Sell |
102,777
-4,333
| -4% | -$20.9K | ﹤0.01% | 2458 |
|
|
2013
Q4 | $540K | Sell |
107,110
-6,518
| -6% | -$31.4K | ﹤0.01% | 2408 |
|
|
2013
Q3 | $576K | Sell |
113,628
-1,747
| -2% | -$9.73K | ﹤0.01% | 2403 |
|
|
2013
Q2 | $572K | Buy |
+115,375
| New | +$549K | ﹤0.01% | 2409 |
|
AllianceBernstein's SCLN Position: Q4 2017 in Review
AllianceBernstein sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 72,228 shares — an estimated $809K sold.
AllianceBernstein first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $3.46M in Q4 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- AllianceBernstein reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- AllianceBernstein sold 72,228 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $809K.
- AllianceBernstein first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- AllianceBernstein's Sciclone Pharmaceuticals Inc position peaked at $3.46M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on AllianceBernstein's 13F filing for Q4 2017, filed 13 Feb 2018.